RATIONALE: External-beam radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving external-beam radiation therapy or implant radiation therapy after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether radiation therapy is more effective than observation when given after surgery in treating stage I endometrial cancer. PURPOSE: This randomized phase III trial is studying external-beam radiation therapy or implant radiation therapy to see how well they work compared with observation in treating patients who have undergone surgery for stage I endometrial cancer.
OBJECTIVES: * Compare the rate of 5-year locoregional relapse in patients undergoing external-beam radiotherapy or vaginal brachytherapy vs observation only after surgery for stage I endometrial cancer. * Compare 5-year rate of distant metastases in these patients. * Determine overall survival rate in these patients. * Determine prognostic factors for relapse and morbidity. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo either vaginal brachytherapy or external-beam radiotherapy. * Arm II: Patients are observed and undergo no further treatment. After completion of study treatment, patients are followed for approximately 83 days. PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
427
Leiden University Medical Center
Leiden, Netherlands
Vaginal relapse
total vaginal relapse and vaginal relapse as first failure
Time frame: 5 years
Rate of distant metastases
total distant relapse and distant relapse as first failure
Time frame: 5 years
Overall survival
all-cause survival (and cancer-related survival)
Time frame: 5 years
Adverse effects
Types and severity graded according to EORTC-RTOG grading system
Time frame: 5 years
Health-related quality of life
Cancer-specific quality of life (EORTC QLQ C-30); patient reported symptoms
Time frame: 5 years
Pelvic relapse
total pelvic relapse and pelvic relapse as first failure
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.